Zhitong Finance App News, ST Renfu (600079.SH) announced that its wholly-owned subsidiary Renfuke Pharmaceutical (Wuhan) Co., Ltd. (“Human Fopke”) recently received an approval number from the US Food and Drug Administration (FDA) for rubiprost softgels.

Rubiprost softgels are approved for the treatment of: (1) adult chronic idiopathic constipation (CIC); (2) opioid-induced constipation (OIC) in adult patients with chronic non-cancerous pain, including those with previous cancer or chronic pain associated with cancer treatment, who do not require frequent (e.g., weekly) opioid dose increases; (3) for constipated irritable bowel syndrome (IBS‑C) in women 18 years and older.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.